ClinicalTrials.gg
CompletedNCT01354704PRENOXAUpdated Nov 3, 2015

Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin

A Phase 4 interventional study of Enoxaparin in Deep Vein Thrombosis, Venous Thrombosis and Adverse Effect of Anticoagulants, sponsored by Les Laboratoires des Médicaments Stériles. Completed at 1 site in Tunisia. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2015-11-03.

Sponsored by Les Laboratoires des Médicaments Stériles · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing enoxaparin in Venous Thrombosis — 3 open to participants now, 3 under way, 1 of them phase 3. Enoxaparin · Venous Thrombosis.

Enrollment
17th of 42
153 · median 114
Started
2011
with 2 others
Phase 4
15 of 42
2 open now
Registered
14th of 42
by date

Among the 42 studies testing enoxaparin in Venous Thrombosis, this one is the 17th largest by enrollment, is one of 3 that started in 2011, is one of 15 in phase 4, and was the 14th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

3 of the 42 studies testing enoxaparin in Venous Thrombosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About enoxaparin

Enoxaparin: first FDA approval 1993 (LOVENOX (PRESERVATIVE FREE)), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing enoxaparin in Venous Thrombosis, or all of them as a file.
02

Study summary

The objectives of the study are:

o Objective ultrasound: Determine the presence or absence of subclinical DVT in practicing ultrasound-Doppler Day7 and Day35, patients who underwent TKA or THA

o Clinical objective To evaluate the efficacy and tolerability clinical Enox ® in these patients compared with the original drug Lovenox ®.

03

Conditions studied

  • Deep Vein Thrombosis
  • Venous Thrombosis
  • Adverse Effect of Anticoagulants

Browse trials for

Keywords

  • deep veinous thrombosis
  • enoxaparin
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • man or woman aged over 18 years, admitted to undergo orthopedic total knee or total hip prosthesis requiring the use of enoxaparin 4000 IU for the Prophylaxis.

Exclusion criteria

Exclusion Criteria:

  • Patient participating in another study.
  • to enoxaparin sodium, heparin unfractionated heparin or other low molecular weight.
  • Patients at risk of major bleeding or uncontrolled including patients with recent stroke
  • Pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Active comparator
    lovenox

    patient under lovenox 4000 IU

    Drug: Enoxaparin

  • Active comparator
    enoxa

    patients under Enoxa 4000 IU

    Drug: Enoxaparin

  • No intervention
    total knee replacement

    patients undergoing total knee replacement

  • No intervention
    total hip replacement

    patient undergoing total knee replacement

Interventions

  • enoxaparin 4000 IU 1 injection/day in subcutaneous.

06

What researchers measure

Primary outcomes

  1. Presence or absence of ultrasound findings in favor of asymptomatic DVT

    After orthopedic surgery, patients are put under LMWH thromboprophylaxis based but some patients may be carrying an asymptomatic DVT. so we'll try the distal venous thrombosis rate in these patients using Doppler ultrasound.

    Time frame: Day 7 and 35

Secondary outcomes

  1. To evaluate the efficacy and tolerability clinical Enox ® in these patients.

    Criteria for evaluating the effectiveness of Enox ®: * Onset or without clinical signs of deep vein thrombosis in clinical postoperative * Onset or without clinical signs of pulmonary embolism after surgery

    Time frame: 3 months

07

Study locations

1 site
  • Hospital Charle Nicolle
    Tunis, Tunis BAB SOUIKA 1006, Tunisia
08

References and documents

Publications

  • 1- Physiopathologie et prévention de la maladie thromboembolique veineuse postopératoire. Charles Marc Samama, Pierre Albaladejo. Sang Thrombose Vaisseaux 2008 ; 20, n°3 :138-43 2- Thromboses veineuses profondes. Dr Jean - Marc Schleich. Département de cardiologie et maladies vasculaires ; CHU de Rennes ; mis à jour le 6 septembre 1998 3- Prévention de la Thrombose veineuse. Dr H. Raybaud - MAJ 2006. Esculape.com : site de médecine générale. 4- Thrombose veineuse profonde. J. - L. Bosson, A. Franco. 1995 SIIM CHU de Grenoble 5- Suivi écho-doppler de thromboses veineuses profondes distales asymptomatique. M.-T BARRELLIER et col. Journal des maladies vasculaires. Masson, 2000, 25, 3 195-200. 6- 83ème Réunion annuelle de la société française de chirurgie orthopédique et traumatologique. Résumé des communications. Revue de chirurgie orthopédique et réparatrice de l'appareil moteur (2008) 94S, S231-S327.
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jul 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2011
First posted
May 17, 2011
Start
Mar 2011
Primary completionActual
Jul 2015
CompletionActual
Oct 2015
Last update
Nov 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01354704
Lead sponsor
Les Laboratoires des Médicaments Stériles
Collaborators
Hopital Charles Nicolle
Responsible party
Sponsor
First posted
May 17, 2011
Start date
Mar 2011
Primary completion
Jul 2015
Completion
Oct 2015
Last update
Nov 3, 2015

Study contacts

mondher kooli, MD
study chair · Hospital Charles Nicolle
Ramzi Bouzidi, MD
principal investigator · Hospital Charle Nicolle
Mustapha Azaiz, MD
principal investigator · Delta Medical Center
Abdelaziz Zarrouk, MD
principal investigator · Hospital Charles Nicollle

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion